00014 A PHASE II STUDY OF THE AGO OVARIAN CANCER STUDY GROUP (AGO-OVAR 2.6): ZD1839 IN COMBINATION WITH TAMOXIFEN IN REFRACTORY OVARIAN CANCER. (1st September 2005) - Sehouli, J.